Half of Novo Nordisk's Wegovy business now comes through out-of-pocket, self-pay channels, a company executive said Monday, and direct cash purchases make up 90% of demand for the Wegovy pill, Reuters reported. The disclosure came at the drugmaker's capital markets day in London, where executives described a pivot toward a more consumer-facing business model.
For many households, the figure reflects a hard reality. Instead of an insurance copay, many people are paying hundreds of dollars a month directly to stay on a weight-loss drug. Cash prices are far lower than list prices, but they still add up to thousands of dollars a year for a medication many patients take long term.
